Bicara Therapeutics Inc. (BCAX) Stock Price & Analysis

Bicara Therapeutics Inc. (BCAX) fell 0.73% to USD 23.17 as of September 8, 2026 at 05:01 UTC, according to Nexqual real-time market data.

BCAX last closed at USD 23.17; the session ranged USD 22.85–23.43 on volume of 296,877 shares. Market capitalization is —, with a 52-week range of USD 10.3–30.99 (NGM). Source: Nexqual, September 8, 2026 at 05:01 UTC.

Key Statistics (as of September 8, 2026 at 05:01 UTC)

Technical Analysis (BCAX)

Nexqual's technical model rates BCAX "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 05:01 UTC.

From Bicara Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• Any patents that issue based on these patent applications, if granted and all appropriate maintenance fees paid, are expected to expire in 2033, not including any patent term adjustment, patent term extension, SPC, or the like. 21 Table of Contents As of March 24, 2026, we also solely own a patent portfolio containing five patent families each containing pending patent applications that, if issued, may provide additional intellectual property protection for ficerafusp alfa.
• In the U.S., the FDA regulates biological products under the Federal Food, Drug, and Cosmetic Act, or the FDCA, the Public Health Service Act, or the PHSA, and their implementing regulations.
• Intellectual Property We seek to protect the intellectual property and proprietary technology that we consider important to our business, including by pursuing patent applications that cover our product candidates and methods of using the same, as well as any other relevant inventions and improvements that we believe to be commercially important to the development of our business.
• We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.

Partnerships

• Contract Transfer and License Agreement with Biocon On October 1, 2019, we entered into a Contract Transfer and License Agreement, or the Biocon Agreement, with Biocon Limited, or Biocon.
• Clinical Trial Collaboration and Supply Agreement with MSD On May 19, 2022, we entered into a Clinical Trial Collaboration and Supply Agreement, or the MSD Agreement, with MSD International GmbH, or MSDIG, and MSD International Business GmbH, MSDIB, and collectively with MSDIG, MSD.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:01 UTC. This page is informational and not investment advice.